Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanzalintinib versus everolimus in advanced neuroendocrine tumors
NL-OMON60690Phase 3Recruiting
- Sponsor
- Exelixis, Inc.
- Start
- Apr 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in apudoma (NET) comparing Zanzalintinib with Everolimus (2 arms). Primary endpoint: Progression-free survival. Started Apr 2026; status: recruiting.
02
Drugs
zanzalintinibeverolimus
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on NL-OMON60690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60690.